Company overview
| Company | RevolKa Ltd. |
| Headquarter | 6-6-40 Aoba, Aramaki, Aoba-ku, Sendai 980-0845, Japan |
| Branch | 7F Shin-Aoyama Building East Building, 1-1-1 Minami-Aoyama, Minato-ku, Tokyo 107-0062, Japan |
| Establish Date | April 7th, 2021 |
| Capital | 215 million yen (As of July 31th, 2025) |
| Management | President and CEO Norio Hamamatsu, Ph.D. Board Director and CSO Mitsuo Umetsu, Ph.D. Board Director Ayumi Iwase Outside Board Director Fumihiro Nakamori, Ph.D. Outside Board Director Kenji Watatani, Ph.D. Corporate Auditor Naoya Onaka |
| Adviser | Technical Advisor Hikaru Nakazawa, Ph.D. Scientific Advisor Kouji Tsuda, Ph.D. Scientific Advisor Hahumi Nishi, Ph.D. Scientific Advisor Yutaka Saito, Ph.D. Strategy Advisor Masanori Sato Medical Advisor Akihiro Kume, M.D., Ph.D. Medical Advisor Toshihiro Ohura, M.D., Ph.D. |
| Business Category | Development of highly functional proteins using AI |
| Number of Employees | 23（including officers and temporary employees) |
| Member Organizations | The Antibody Society of Japan Japan Bioindustry Association Sendai Chamber of Commerce and Industry |
Origin of company name
"RevolKa" is derived from the Latin word for evolution (evolutio) and the Ainu word for raise (reska). Our company logo takes inspiration from the developing fetus and represents that to raise (R of reska) nurtures evolution (e of evolution) with care.
We have evolved the protein selected by life as a functional molecule into a frontier that could not be reached in nature by using evolutionary molecular engineering that mimics evolution in vitro using artificial intelligence technology as a guide. We will grow it as a functional molecule required by various fields focusing on medicine.
History
| April, 2021 | Established RevolKa Ltd. in Chuo-ku, Tokyo as a venture from Tohoku University |
| June, 2021 | Concluded a joint research agreement with Tohoku University |
| June, 2021 | Completed funding in the first seed round |
| January, 2022 | Opened Sendai Lab in Aoba-ku, Sendai |
| January, 2022 | Completed funding in the second seed round |
| March, 2022 | Concluded a joint research agreement with Sumitomo Dainippon Pharma Co., Ltd. (now Sumitomo Pharma Co., Ltd.) |
| April, 2022 | Opened Tokyo Laboratory in Chuo-ku, Tokyo |
| May, 2022 | Completed Series A round of funding |
| September, 2022 | Opened US office in Cambridge, Massachusetts, USA |
| October, 2022 | Concluded a joint research agreement with Tokyo Medical and Dental University |
| November, 2022 | Moved Tokyo Laboratory to Bunkyo-ku, Tokyo |
| July, 2023 | Moved Head office to Bunkyo-ku, Tokyo |
| September, 2023 | Closed Tokyo Laboratory |
| January, 2024 | Completed Series A extension round of funding |
| August, 2024 | Completed Series A extension round of additionalfunding |
| February, 2025 | Moved Head office to Aoba-ku, Sendai |
| May&July, 2025 | Completed Series A extension round of additionalfunding |
| December, 2025 | Moved Tokyo office to Minato-ku, Tokyo |
Co-founder
SHIRO KATAOKA
MITSUO UMETSU
HIKARU NAKAZAWA
Locations
RevolKa head office・Sendai Lab
6-6-40-208･301･309 Aoba, Aramaki, Aoba-ku, Sendai 980-8579, Japan
From the nearest station
About 2-minutes walk from the North Exit of "Aobayama Station" on Sendai Subway Tozai Line
About 2-minute walk from the south Exit of "Aobayama Station" on Sendai Subway Tozai Line
RevolKa Tokyo office
7F Shin-Aoyama Building East Building, 1-1-1 Minami-Aoyama, Minato-ku, Tokyo 107-0062, Japan
From the nearest station
Directly connected to "Aoyama 1cyoume Station" on the Tokyo Metro Giznza Line, Hanzomon Line, and Oedo Line
RevolKa U.S. Office
One Broadway, Cambridge, MA 02142, USA